SCHEMBL4902888

SCHEMBL4902888

COc1ccc2c(N(C(=O)O)N(c3ccc(N(CCCl)CCCl)cc3)c3c(C)nc4ccc(OC)cc4c3NN(C(=O)O)c3ccc(N(CCCl)CCCl)cc3)cc(C)nc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.37
KDM4E B2RXH2 7/20 0.36
HPGD P15428 6/20 0.36
HSD17B10 Q99714 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 3/20 0.35
GAA P10253 2/20 0.35
GLA P06280 1/20 0.35
KMT2A Q03164 4/20 0.35
KCNH2 Q12809 2/20 0.35
MEN1 O00255 2/20 0.35
PLA2G2A P14555 1/20 0.34
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907565 0.72 NQO2 (0.49) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL4910373 0.68 IGF1R (0.61) KDM4EHSD17B10CYP3A4CYP2C9CYP2C19
SCHEMBL4913217 0.68 IGF1R (0.61) POLBKMT2AKCNH2MEN1SMN1; SMN2
SCHEMBL4914900 0.67 KCNH2 (0.56) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL4906398 0.66 OPRK1 (0.47) KDM4ECYP2C19MAPTKMT2AMEN1
SCHEMBL4907570 0.66 NQO2 (0.55) POLBKMT2AKCNH2MEN1SMN1; SMN2
SCHEMBL4901504 0.65 POLB (0.40) POLBKMT2AMEN1
SCHEMBL4940288 0.64 HDAC3 (0.36) ALDH1A1KDM4EHSD17B10CYP3A4CYP2C9
SCHEMBL15101593 0.64 ATM (0.55) ALDH1A1MAPTPOLBGAAKMT2A
SCHEMBL4906410 0.63 L3MBTL1 (0.42) ALDH1A1NPSR1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222297-B2 e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma ACADEMIA SINICA (TW) 2012-07-17 US disclosed
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents ACADEMIA SINICA (TW) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents WEE1, PCNA, ATIC ALDH1A1 1144/4885KDM4E 873/4885HPGD 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.